This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (20)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

JAMA. 2000;283:2228.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

The FDA wishes to inform physicians of the removal from the market of troglitazone (Rezulin, Parke-Davis/Warner-Lambert Co, Morris Plains, NJ), a treatment for type 2 diabetes mellitus, and cisapride (Propulsid, Janssen Pharmaceutica Inc, Titusville, NJ), a treatment for severe heartburn.

Troglitazone has been associated with rare but severe liver toxicity since 1997, and close monitoring of liver function of patients using the drug was recommended. A year ago, when it was the only drug of an important class, an FDA advisory committee recommended that troglitazone continue to be available for patients whose disease was not well-controlled by other medications, on the grounds that its benefit to the great majority of patients far outweighed the risk.

The FDA concurred while awaiting postmarketing experience with two subsequently approved drugs for type 2 diabetes mellitus, rosiglitazone (Avandia, SmithKline Beecham Pharmaceuticals, Philadelphia) and pioglitazone (Actos, Takeda Pharmaceuticals America Inc and Eli Lilly, Indianapolis). When . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Refining Insights into High-Affinity Drug Binding to the Human Ether-a-go-go-Related Gene Potassium Channel
Hancox and James
Mol. Pharmacol. 2008;73:1592-1595.
ABSTRACT | FULL TEXT  

The Long and Short of a Constipation-Reducing Medication
Moss
NEJM 2008;358:2402-2403.
FULL TEXT  

Challenges in Systematic Reviews of Complementary and Alternative Medicine Topics
Shekelle et al.
ANN INTERN MED 2005;142:1042-1047.
ABSTRACT | FULL TEXT  

Expression and function of KCNH2 (HERG) in the human jejunum
Farrelly et al.
Am. J. Physiol. Gastrointest. Liver Physiol. 2003;284:G883-G895.
ABSTRACT | FULL TEXT  

Implications of Cytochrome P450 Interactions When Prescribing Medication for Hypertension
Flockhart and Tanus-Santos
Arch Intern Med 2002;162:405-412.
ABSTRACT | FULL TEXT  

Cochrane's epitaph for cisapride in childhood gastro-oesophageal reflux
Bourke and Drumm
Arch. Dis. Child. 2002;86:71-72.
FULL TEXT  

Coprescribing and Codispensing of Cisapride and Contraindicated Drugs
Jones et al.
JAMA 2001;286:1607-1609.
ABSTRACT | FULL TEXT  

Task Force on Sudden Cardiac Death of the European Society of Cardiology
Priori et al.
Eur Heart J 2001;22:1374-1450.
 

Time Trends in the Coprescribing of Cisapride and Contraindicated Drugs in Umbria, Italy
Raschetti et al.
JAMA 2001;285:1840-1841.
FULL TEXT  

Avidity, Potency, and Cross-Reactivity of Monoclonal Antibodies to Pneumococcal Capsular Polysaccharide Serotype 6B
Sun et al.
Infect. Immun. 2001;69:336-344.
ABSTRACT | FULL TEXT